Trial Profile
A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 26 May 2022 Planned End Date changed from 30 Sep 2026 to 6 May 2026.
- 26 May 2022 Planned primary completion date changed from 30 Sep 2024 to 6 May 2024.
- 26 May 2022 Status changed from recruiting to active, no longer recruiting.